Navigation Links
Largest Study to Date Shows Significant Reductions in Risks of Blood Clots and Reintervention With CYPHER(R) Sirolimus-eluting Coronary Stent Compared to Taxus Stent
Date:9/4/2007

et lesion revacularization or TLR).

According to this comprehensive analysis of all head-to-head clinical studies between the CYPHER(R) Stent and the Taxus Stent, a blood clot (stent thrombosis) is 34 percent less likely to form in patients implanted with the CYPHER(R) Stent than in patients who receive the Taxus Stent -- a statistically significant difference [hazard ratio (HR) 0.66, 95 percent confidence interval (CI) 0.46 to 0.94, p=0.02]. In addition, the CYPHER(R) Stent significantly lowered the risk of reintervention by 26 percent versus the Taxus Stent (HR 0.74, CI 0.63 to 0.87, p<0.001).

While the overall risk of death was not significantly different between the two drug-eluting stents (HR 0.92, CI 0.74 to 1.13, p=0.43), the authors of the meta-analysis identified a trend toward a lower risk of heart attack with the CYPHER(R) Stent versus the Taxus Stent (HR 0.84, CI 0.69 to 1.03, p=0.10), especially after the first year of follow-up.

Events occurring after the first year of stent placement have fueled the discussion surrounding the safety of drug-eluting stents. When only patient- level data were used, the authors were able to assess the occurrence of events after the first year of follow-up. In this analysis, there was a significant 70 percent reduction in blood clots (p=0.004) and a 55 percent reduction in repeat heart attacks (p=0.006) in patients who received the CYPHER(R) Stent compared to patients implanted with a Taxus Stent.

"This meta-analysis substantially enriches the large body of evidence that interventional cardiologists have at their disposal to make the right choice for their patients," said David E. Kandzari, M.D., F.A.C.C., F.S.C.A.I, Chief Medical Officer, Cordis Corporation. "Drug-eluting stents, like the CYPHER(R) Stent, continue to provide significant benefits for patients with coronary artery disease."

For this analysis of randomized controlled trials, the gold standard of clinical evidence in medicine, i
'/>"/>

SOURCE Cordis Corporation
Copyright©2007 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related medicine technology :

1. Largest Cervical Cancer Vaccine Efficacy Trial Shows Cervarix Provides Excellent Protection Against Lesions Caused by Most Common Cancer-Causing Virus Types
2. Largest National U.S. Healthcare Facility MRSA Study Reveals Infection Rates Eight Times Greater Than Previous Estimates
3. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
4. Clinical Study Shows Regenecare Relieves Pain and Itching of Skin Rashes Caused by Widely Used Cancer Drugs
5. Cell Therapeutics, Inc. Management to Discuss Todays Announcement of Interim Pixantrone Study Results
6. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
7. Reaction to Avandia Warnings Stronger Among Internists Than Endocrinologists, According to Study by GfK Market Measures
8. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
9. Actemra (tocilizumab) Third Phase III Study Results Show Significant Improvement in Symptoms of Patients with Rheumatoid Arthritis
10. Protox Announces Positive Clinical Data from Prostate Cancer Study
11. International ENDORSE Study Shows That the Majority of Hospitalized Patients Surveyed are at Risk for VTE and Many do not Receive Recommended VTE prophylaxis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/22/2008)...velopment Initiative bring MJFF,s,current active i...y 20,2009, NEW YORK, July 22 /PRNewswire-USNewsw...f transformative treatments and a cure for Parkins...rkinson,s Research has awarded,$2.7 million in tot...rds,were granted under MJFF,s Therapeutics Develop...
(Date:7/22/2008)... Apidra(R) Resulted in Significant, Reductions in ... Algorithm Used, ...s from the "Adjust to,Target in Type 2 Diabetes: C...unting for Adjustment of Mealtime Insulin Glulisin...Association,s (ADA) medical journal,Diabetes Care...
(Date:7/22/2008)...a University Medical Center Based on Ros...The Test Differentiates Squamous From Non-Squamous...Squamous-Cell Carcinoma of the Lung With Se...ent,This is the First CLIA Approved Test Which Lev...rs for Accurate Diagnosis of Lung Cancer, REHOVOT...
(Date:7/22/2008)...ew Approach of LASH (Laser Assisted Scar Heali...y, MARSEILLES, France, July 22 /- Ek...omedicine company, which develops first-in-class,l...duction, announced today,the publication of a scie...reporting the results of a pilot study on cutaneou...
Breaking Medicine Technology:Michael J. Fox Foundation Awards $2.7 Million for Industry Efforts to Speed New Parkinson's Therapeutics 2Michael J. Fox Foundation Awards $2.7 Million for Industry Efforts to Speed New Parkinson's Therapeutics 3Newly Published Study Results Showed That Two Mealtime Insulin Dosing Algorithms Were Effective for Patients with Type 2 Diabetes 2Newly Published Study Results Showed That Two Mealtime Insulin Dosing Algorithms Were Effective for Patients with Type 2 Diabetes 3Newly Published Study Results Showed That Two Mealtime Insulin Dosing Algorithms Were Effective for Patients with Type 2 Diabetes 4First Cancer Diagnostic Test Based on Rosetta Genomics' Proprietary MicroRNA Technology Receives Regulatory Approval 2First Cancer Diagnostic Test Based on Rosetta Genomics' Proprietary MicroRNA Technology Receives Regulatory Approval 3First Cancer Diagnostic Test Based on Rosetta Genomics' Proprietary MicroRNA Technology Receives Regulatory Approval 4First Cancer Diagnostic Test Based on Rosetta Genomics' Proprietary MicroRNA Technology Receives Regulatory Approval 5Ekkyo Describes the First Benefits of Controlled Hyperthermia in Humans in "Lasers in Surgery and Medicine" 2Ekkyo Describes the First Benefits of Controlled Hyperthermia in Humans in "Lasers in Surgery and Medicine" 3CEL SCI Corporation Releases Letter to Shareholders 10228 1CEL SCI Corporation Releases Letter to Shareholders 10228 2CityVoter and ExerciseTV Partner to Launch ExerciseTV Top Trainer a Nationwide Search for Americas Top Fitness Trainers 10225 1CityVoter and ExerciseTV Partner to Launch ExerciseTV Top Trainer a Nationwide Search for Americas Top Fitness Trainers 10225 2CityVoter and ExerciseTV Partner to Launch ExerciseTV Top Trainer a Nationwide Search for Americas Top Fitness Trainers 10225 3CityVoter and ExerciseTV Partner to Launch ExerciseTV Top Trainer a Nationwide Search for Americas Top Fitness Trainers 10225 4Clontech Laboratories Inc Releases the ProteoTuner 28TM 29 Systems 2762 1Clontech Laboratories Inc Releases the ProteoTuner 28TM 29 Systems 2762 2Arbor Surgical Technologies Announces Series C Financing and Licensing Agreement with Medtronic 2759 1Arbor Surgical Technologies Announces Series C Financing and Licensing Agreement with Medtronic 2759 2
...GLE PARK, N.C. & SHERBROOKE, Quebec--(BUSINESS...biopharmaceutical,company developing small molecul...metabolic diseases, today announced positive,resul...lerating,gastric emptying in diabetic patients wit...tudy were presented at the American,Diabetes Assoc...
...technology Company updates progress and upcoming,m...26, 2007 /PRNewswire-FirstCall/ - SemBioSys,Geneti...tfolio of,therapeutic proteins for metabolic and c...eclinical data supporting the,development of plant...esented its findings at the 67th Scientific Sessio...
Other Medicine Technology:Tranzyme Pharma Presents Initial Phase IIa Data for its Novel,Ghrelin Agonist, TZP-101, in Patients with Diabetic Gastroparesis 2Tranzyme Pharma Presents Initial Phase IIa Data for its Novel,Ghrelin Agonist, TZP-101, in Patients with Diabetic Gastroparesis 3SemBioSys Presents Positive Insulin Data at the American Diabetes,Association Conference 2SemBioSys Presents Positive Insulin Data at the American Diabetes,Association Conference 3SemBioSys Presents Positive Insulin Data at the American Diabetes,Association Conference 4
(Date:7/25/2008)... HOUSTON, July 25 /PRNewswire/ -- The Elekta Famil...cancer treatment solutions at the 2008,American As...meeting,demonstrating how the joint forces of Ele...iation therapy planning and delivery solutions tha...ter experience for,patients, as well as enhance cl...
(Date:7/25/2008)...urday can be toughest for those trying to drop pou...althDay News) -- Anyone who has avoided Monday mor...nds are not a dieter,s friend. , Now, researche...s about weekends being their undoing: Most people ...ng to lose weight. , "Weekend indulgences can w...
(Date:7/25/2008)... The Drug Information Associ...FDA) will host the Critical Path Initiative (CPI) ...r 15 -16; Bethesda, MD) and the Critical Path Tran.... , Horsham, PA (PRWEB) J... Information Association (DIA)] and the Food and D...
(Date:7/24/2008)... Hoag to lease hospital faci... Newport Beach, CA (Vocus) July 24, 2008 -- Hoa...reement with HCP, Inc. (NYSE: HCP), a Real Estate ...to lease its 175-bed hospital facility on Sand Can..., , , ,The facility is currently operated by Tene...
Breaking Medicine News(10 mins):Health News:Elekta Family of Companies to Highlight Cancer Treatment Solutions at 2008 AAPM Annual Meeting 2Health News:Elekta Family of Companies to Highlight Cancer Treatment Solutions at 2008 AAPM Annual Meeting 3Health News:Weekends Tough on the Diet 2Health News:Weekends Tough on the Diet 3Health News:DIA And FDA To Host Two Important Critical Path Workshops 2Health News:DIA And FDA To Host Two Important Critical Path Workshops 3Health News:Hoag Hospital Announces Agreement to Open Irvine Campus 2
...esperate to stun people with the way she looks, fo....3 kilograms in one month . The 26-year-old is on ...by her celeb trainer Harley Pasternak, and she eve...e nutritional meals delivered to her doorstep. Sim...
...ted that circumcision 'significantly' cuts HIV ris...ess important as a deterrent to the global AIDS pa...bott who conducted statistical empirical research ...the world conducted the study. He found that the n...
...stitute have found in animal models just how great...celerating breast cancer . Until this study, the s...east cancer had not been clearly established, and ...dings could lead to a better understanding of the ...
...red an inquiry into the alleged incident of a 15-y...on, an official said Thursday. In April, Dileepa...ction operation under his parents' supervision at ...spital in Manapparai, about 450 km from the state ...
Other Medicine News:Health News:Male Circumcision Overstated as Deterrent to Global AIDS Pandemic 2Health News:Researchers Have Found the Role of Protein in Accelerating Breast Cancer Progression 2Health News:Researchers Have Found the Role of Protein in Accelerating Breast Cancer Progression 3
...iagnostic collection software. Sandman Elite versi...collection software offers customizable digital fi...post recording. The scoring displays a list of sco...ing current number of events, frequency and averag...
...ur SleepWorks software and Hyppo headbox. XLTEK's ...ostic sleep-testing needs. It's compliant, accurat...ked up by 24/7 support provided by a team of knowl...t, you can expand your capabilities to include cli...
... in the Beehive product line, combines decades of ...ogy of the 21st century. Beehive Millennium is a p..., providing complete data acquisition, recording a...ilepsy monitoring applications. Beehive Millennium...
...ged unit capable of handling a wide range of stimu... research laboratories. The built-in isolation cir...s artifacts. The twin pulse circuit makes this sti...n Signal Marker For those investigators requiring ...
Medicine Products: